Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 210
- Registration Number
- NCT00577993
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2013-08-30
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 94
- Registration Number
- NCT00575406
- Locations
- 🇦🇹
Universitaetsklinik Innsbruck/ Klinik für Innere Medizin, Innsbruck, Austria
🇦🇹A.ö. Landeskrankenhaus Leoben, Leoben, Austria
🇦🇹Krankenhaus d. Barmherzigen Schwestern Linz, Linz, Austria
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT00562965
- Locations
- 🇺🇸
Wenatchee Valley Medical Center, Wenatchee, Washington, United States
🇺🇸Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States
🇺🇸Facey Medical Group, Mission Hills, California, United States
Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2007-11-09
- Target Recruit Count
- 94
- Registration Number
- NCT00556127
- Locations
- 🇮🇹
Centro Trapianti Midollo Osseo, P.O. Businco, Cagliari, Italy
🇮🇹Ospedale S. Gerardo, Monza, Italy
🇮🇹Osp. maggiore della Carità, Novara, Italy
Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas
- First Posted Date
- 2007-11-08
- Last Posted Date
- 2013-06-11
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 8
- Registration Number
- NCT00555464
- Locations
- 🇺🇸
Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
Adult ALL Treatment at Diagnosis
- Conditions
- Locations
- 🇮🇹
Ist.Ematologia e Oncologia Medica L.e A. Seragnoli, Bologna, Italy
🇮🇹Ospedale Reg. A di Summa, Brindisi, Italy
🇮🇹Istituto di Ematologia- Ospedale San Carlo, Potenza, Italy
LAL-BR/2001: Study Treatment to Low Risk ALL
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 150
- Registration Number
- NCT00526175
- Locations
- 🇪🇸
Basurtuko Ospitalea, Basurto, Spain
🇪🇸Complejo Hospitalario Universitario de Albacete, Albacete, Spain
🇪🇸Hospital General de Alicante, Alicante, Spain
LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 40
- Registration Number
- NCT00526409
- Locations
- 🇪🇸
Hospital Niño Jesús, Madrid, Spain
🇪🇸Hospital materno Infantil vall d'Hebrón, Barcelona, Spain
🇪🇸Hospital Infantil Carlos Haya, Málaga, Spain
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2010-01-05
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT00526305
- Locations
- 🇪🇸
Hospital General de Segovia, Segovia, Spain
🇪🇸Hospital Universitario de Canarias, Tenerife, Spain
🇪🇸H.U. Virgen del Rocio, Sevilla, Spain
Treatment of Tumors of the Choroid Plexus Epithelium
- Conditions
- Interventions
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2020-02-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT00500890
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.